Zimmer Biomet Holdings Overview
Zimmer Biomet Holdings (ZBH) has a ROE of 6.39%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow6.39%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Zimmer Biomet Holdings (ZBH) currently reports a ROE of 6.39%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Zimmer Biomet Holdings's ROE history and peer comparisons.
Zimmer Biomet Holdings's ROE of 6.39% is higher than the Healthcare sector average of -100.59%. That is roughly 106.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Zimmer Biomet Holdings's current 6.39% should be judged against Healthcare norms (sector average: -100.59%) and against ZBH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 6.39%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Zimmer Biomet Holdings, and consider following ZBH for alerts when major investors trade the stock.
Zimmer Biomet Holdings is classified in the Healthcare sector. On ROE, it currently shows 6.39% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZBH with unrelated industries.
